Phase II Study of Weekly Paclitaxel, Carboplatin and Irinotecan in Patients With Advanced Non-Small Cell Lung Cancer Nad Malignant Plerual Effusion
Lung cancer is the leading cancer death in many countries of the world including Singapore.
Non-small cell lung cancer (NSCLC) consists of 80-85% of lung cancers, and is a major health
problem. The main etiology of lung cancer is well recognized and established to be cigarette
smoking which accounts for up to 80% of the cases in the western countries. Due to success
of anti-smoking campaig, we anticipate to see less smoking related lung cancer and more
non-smoking related lung cancer which is rising rapidly. For eg, currently in Singapore,
smoking only accounts for 50-60% of all lung cancers, this is particularly true in female
patients, as smoking occured in 30-40% of female lung cancer patients only.
It is unclear if there is any significant difference in the fundamental biology between
smoking and non-smoking related lung cancers, particularly in areas of natural course of
disease, genetic changes of tumor cells, clinical presentation, response to treatment or
survival. These are potential aspects for further investigation.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the efficacy and toxicity of the weekly combination chemotherapy of paclitaxel, carboplatin and irinotecan in Stage IIIB and IV NSCLC patients with malignant pleural effusion
Alex Chang, MD
Johns Hopkins SIngapore International Medical Center
Singapore: Domain Specific Review Boards